(Q35985899)

11 August 2017

Dose-finding study of peginesatide for anemia correction in chronic kidney disease patients (English)

1 reference

chronic renal insufficiency

11 August 2017

1 reference

10

Władysław Sułowicz

1 reference

11 August 2017

2

Andrzej Wiecek

1 reference

11 August 2017

8

Michal Mysliwiec

1 reference

11 August 2017

9

Olgierd Smolenski

1 reference

ORCID Public Data File 2021

11 August 2017

1 reference

author name string

Iain C Macdougall

1

1 reference

11 August 2017

Beatriz Tucker

3

1 reference

11 August 2017

Magdi Yaqoob

4

1 reference

11 August 2017

Ashraf Mikhail

5

1 reference

11 August 2017

Michal Nowicki

6

1 reference

11 August 2017

Iain MacPhee

7

1 reference

11 August 2017

Martha Mayo

11

1 reference

11 August 2017

Carol Francisco

12

1 reference

11 August 2017

Krishna R Polu

13

1 reference

11 August 2017

Peter J Schatz

14

1 reference

11 August 2017

Anne-Marie Duliege

15

1 reference

11 August 2017

22 September 2011

1 reference

Clinical Journal of the American Society of Nephrology

11 August 2017

1 reference

11 August 2017

6

1 reference

11 August 2017

11

1 reference

11 August 2017

2579-2586

1 reference

A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3359570

Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3359570

Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3359570

Anemia and health-related quality of life in adolescents with chronic kidney disease.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3359570

Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3359570

The effect of anemia treatment on selected health-related quality-of-life domains: a systematic review

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3359570

Optimizing the use of erythropoietic agents-- pharmacokinetic and pharmacodynamic considerations

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3359570

C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3359570

Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3359570

Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3359570

Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3359570

European best practice guidelines 6-8: assessing and optimizing iron stores

24 September 2018

1 reference

12 December 2020

Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients

1 reference

12 December 2020

Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo)

1 reference

12 December 2020

Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial

1 reference

12 December 2020

The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease

1 reference

12 December 2020

Identifiers

DOI

10.2215/CJN.10831210

1 reference

11 August 2017

1 reference

11 August 2017

PubMed publication ID

21940838

1 reference